Project details
Japanese biopharmaceutical start-up seeks about USD 10 million B-round financing
| Project region | Japan |
|---|---|
| Industry | Pharmeceuticals & Chemical |
| Total value of the target | N/A |
| Expected target net rate of return after deducting all taxes and fees | N/A |
| Validity period of pending order | 365 |
CONTACT ADVISOR
| Project highlights | DNA & RNA editing - technology licencing |
|---|---|
| Project description |
The Japanese company develops DNA and RNA editing technology in the field of innovative medicines and chemical medicines, whose intellectual property assets may be granted rights to others under a licence, sublicence or other contract. The company's core is RNA-PPR technology. Its current products include repetitive motif RNA control platform, RNA splicing control platform and protein translation activation platform. The company seeks about USD 10 million (JPY 13 billion) B-round financing. |
We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.
Have Any Questions?
Reach out to our local experts, we’ll respond within one business day.
Our Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us
